Literature DB >> 16932988

Patient choice of treatment for postpartum depression: a pilot study.

T B Pearlstein1, C Zlotnick, C L Battle, S Stuart, M W O'Hara, A B Price, M A Grause, M Howard.   

Abstract

OBJECTIVE: The lack of systematic efficacy research makes the selection of optimal treatment for postpartum depression (PPD) difficult. Moreover, the treatment decisions for women with PPD who are breastfeeding are heavily influenced by their concerns about infant exposure to antidepressant medication. The objective of this pilot trial was to examine the clinical characteristics of women with PPD associated with treatment selection.
METHOD: This open pilot trial offered 23 women with PPD one of 3 treatment options: sertraline, interpersonal psychotherapy (IPT), or their combination administered in an outpatient mental health setting over 12 weeks. Baseline and treatment outcome measures included the Hamilton Rating Scale for Depression (HRSD), the Beck Depression Inventory (BDI) and the Edinburgh Postnatal Depression Scale (EPDS).
RESULTS: Completers across all 3 treatment groups (n = 18) experienced significant clinical improvement with each of the 3 treatment modalities on the HRSD (p < 0.001), BDI (p < 0.001) and EPDS (p < 0.001). There were trends for women with a prior depression to more frequently choose sertraline as a treatment (alone or with IPT, p = 0.07), and for women who were breastfeeding to choose sertraline (alone or with IPT, p = 0.10) less frequently.
CONCLUSION: In this small sample of women with PPD, most women chose IPT with or without sertraline. A larger randomized study could further confirm the suggested predictors of treatment selection identified in this study: previous depression and breastfeeding status.

Entities:  

Mesh:

Year:  2006        PMID: 16932988     DOI: 10.1007/s00737-006-0145-9

Source DB:  PubMed          Journal:  Arch Womens Ment Health        ISSN: 1434-1816            Impact factor:   3.633


  29 in total

Review 1.  Recognizing and treating peripartum depression.

Authors:  Bettina Hübner-Liebermann; Helmut Hausner; Markus Wittmann
Journal:  Dtsch Arztebl Int       Date:  2012-06-15       Impact factor: 5.594

Review 2.  Use of contemporary antidepressants during breastfeeding: a proposal for a specific safety index.

Authors:  Salvatore Gentile
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

3.  Interpersonal psychotherapy for postpartum depression.

Authors:  Scott Stuart
Journal:  Clin Psychol Psychother       Date:  2012 Mar-Apr

4.  Seeing the silver lining: cognitive reappraisal ability moderates the relationship between stress and depressive symptoms.

Authors:  Allison S Troy; Frank H Wilhelm; Amanda J Shallcross; Iris B Mauss
Journal:  Emotion       Date:  2010-12

5.  Are maternal depression or symptom severity associated with breastfeeding intention or outcomes?

Authors:  Debra L Bogen; Barbara H Hanusa; Eydie Moses-Kolko; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2010-06-15       Impact factor: 4.384

Review 6.  Pharmacotherapy of postpartum depression: an update.

Authors:  Deborah R Kim; C Neill Epperson; Amy R Weiss; Katherine L Wisner
Journal:  Expert Opin Pharmacother       Date:  2014-04-29       Impact factor: 3.889

Review 7.  Oxytocin and postpartum depression: delivering on what's known and what's not.

Authors:  Sohye Kim; Timothy A Soeken; Sara J Cromer; Sheila R Martinez; Leah R Hardy; Lane Strathearn
Journal:  Brain Res       Date:  2013-11-14       Impact factor: 3.252

Review 8.  Depression and Anxiety During Pregnancy: Evaluating the Literature in Support of Clinical Risk-Benefit Decision-Making.

Authors:  Katharine Baratz Dalke; Amy Wenzel; Deborah R Kim
Journal:  Curr Psychiatry Rep       Date:  2016-06       Impact factor: 5.285

Review 9.  Pharmacotherapy of postpartum depression.

Authors:  Teresa Lanza di Scalea; Katherine L Wisner
Journal:  Expert Opin Pharmacother       Date:  2009-11       Impact factor: 3.889

Review 10.  Perinatal depression: treatment options and dilemmas.

Authors:  Teri Pearlstein
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.